Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285354 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5168130 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4778591 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4773208 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL2805480 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535294 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5651326 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL514304 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL581065 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535321 | 1.00 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-04-24 | — | — | US | disclosed |
| EP-4448519-A1 | N-1 TRIAZOLE SUBSTITUTED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | Solventum Intellectual Properties Company (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401523-A | N-1 triazole substituted imidazoquinolines, conjugates thereof and methods | 舒万诺知识产权公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023111726-A1 | N-1 TRIAZOLE SUBSTITUTED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2430074-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | University Court Of The University Of Aberdeen (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | disclosed |
| US-6767903-B1 | ANTIANDROGEN THERAPY FOR PROSTATE CANCER | SCHERING AG (DE) | 2004-07-27 | — | — | US | disclosed |
| EP-1140972-B1 | NEW 7-ALPHA, 17-ALPHA-BIS-ALKYLATED TESTOSTERONE DERIVATIVES AND THEIR USE IN LONG-TERM THERAPY OF ANDROGEN-DEPENDENT DISEASES | SCHERING AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| EP-0295056-A1 | Anti-inflammatory furanones | ALLERGAN, INC (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0138504-B1 | STEROID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-20 | — | — | EP | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| US-4659516-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-21 | — | — | US | disclosed |
| US-4657916-A | PREVENTIVE AND HEALING AGENTS FOR DISEASES CAUSED BY LIPOXYGENASE METABOLITES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-04-14 | — | — | US | disclosed |
| EP-0177764-A1 | Quinoline-n-oxide derivative and pharmaceutical composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1986-04-16 | — | — | EP | disclosed |
| EP-0138504-A2 | Steroid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-04-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | IFNG, IFNAR1, IL2 | DUT 581/4885 |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | PDXK, RAD54L, CDKL5 | DUT 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.